A Phase 3 Evaluation of Daclatasvir and Sofosbuvir in Treatment Naive and Treatment Experienced Subjects With Genotype 3 Chronic Hepatitis C Infection
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Daclatasvir (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Acronyms ALLY-3
- Sponsors Bristol-Myers Squibb
- 24 May 2016 Results (pooled analysis of this and other study, n = 98) assessing safety and efficacy of daclatasvir Plus sofosbuvir with or without ribavirin in patients with advanced fibrosis or cirrhosis presented at the Digestive Disease Week 2016.
- 17 Apr 2016 Results (sequencing analysis, n = 17) presented at The International Liver Congress™ 2016.
- 17 Apr 2016 Pooled safety and efficacy analysis of ALLY-3 and ALLY-3+ studies (n=168) were presented at The International Liver Congress 2016.